Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in acute myelogenous leukemia therapy.

Mary E King1, Jacob M Rowe

  • 1Medical and Scientific Communications, Boulder, Colorado, USA.

The Oncologist
|December 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features.

Nature cancer·2025
Same author

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Blood advances·2025
Same author

A Workflow Enabling the Automated Synthesis, Chain-End Degradation, and Rapid Mass Spectrometry Analysis for Molecular Information Storage in Sequence-Defined Oligourethanes.

JACS Au·2025
Same author

Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.

Haematologica·2025
Same author

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

British journal of haematology·2024
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Recent advancements in acute myelogenous leukemia (AML) treatment include improved prognostic factors, the adoption of reduced-intensity conditioning in allogeneic bone marrow transplantation, and the development of targeted therapies for specific genetic subtypes.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Acute myelogenous leukemia (AML) treatment has seen significant progress.
  • Key areas of advancement include prognostic factor refinement, bone marrow transplantation techniques, and novel therapeutic agents.

Purpose of the Study:

  • To summarize recent developments in AML treatment.
  • To highlight progress in risk stratification, transplantation, and targeted therapies.

Main Methods:

  • Review of recent literature on prognostic factors, allogeneic bone marrow transplantation, and new therapies for AML.
  • Analysis of trends in risk determination using molecular markers.
  • Evaluation of reduced-intensity conditioning and alternative donor utilization in transplantation.

Related Experiment Videos

  • Assessment of outcomes for HLA-identical sibling and unrelated-donor transplants based on remission status.

    • Main Results:

    • Prognostic factor research is shifting towards molecular markers for improved risk assessment.
    • Reduced-intensity conditioning is widely adopted in allogeneic transplantation, though prospective data are needed.
    • Alternative donors show promise, but outcomes are poor in active disease.
    • HLA-identical sibling and unrelated-donor transplants yield better survival in first complete remission (CR1) compared to later remissions.
    • Cord blood is a viable option for hematopoietic transplantation.
    • New targeted therapies are under development and show potential for genetically defined AML subtypes.

    Conclusions:

    • Advances in prognostic factors, transplantation strategies, and targeted therapies are improving AML treatment.
    • Further prospective studies are required to fully establish the benefits of reduced-intensity conditioning.
    • Tailoring therapy to specific genetic subtypes of AML represents a promising future direction.